Science Explorer Back to mapMap
Discussion
Company · Brisbane · Australia

Vaxxas (Australia)

vaxxas.comROR OpenAlex
Research works
10
▲ 67% vs 2018-21
Citations
269
27.0 per fractional work
Top-10% rate
10.0%
all institutions 10.0%
Open access
95%
world 40%
International
32%
world 18%
Vaxxas (Australia)

Not ranked overall: Vaxxas (Australia) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Vaxxas (Australia) work in?

In all years, 53% of research at Vaxxas (Australia) is in Life Sciences, 40% in Health Sciences. Its largest fields are Medicine (40%), Immunology and Microbiology (17%), Pharmacology, Toxicology and Pharmaceutics (15%). It does 1.8× the world's share of Life Sciences.

Life Sciences: 5 fractional works · 53.2% of its workImmunology and Microbiology: 2 fractional works · 16.6% of its workImmunology: 1 fractional works · 12.3% of its workVirology: 0 fractional works · 4.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workPharmacology, Toxicology and Pharmaceutics: 2 fractional works · 15.2% of its workPharmaceutical Science: 2 fractional works · 15.2% of its workBiochemistry, Genetics and Molecular Biology: 1 fractional works · 13.8% of its workMolecular Biology: 1 fractional works · 6.7% of its workGenetics: 0 fractional works · 4.4% of its workBiotechnology: 0 fractional works · 1.6% of its workCell Biology: 0 fractional works · 1.1% of its workAgricultural and Biological Sciences: 1 fractional works · 6.7% of its workAnimal Science and Zoology: 1 fractional works · 6.7% of its workNeuroscience: 0 fractional works · 0.7% of its workNeurology: 0 fractional works · 0.7% of its workHealth Sciences: 4 fractional works · 40.3% of its workMedicine: 4 fractional works · 40.3% of its workInfectious Diseases: 1 fractional works · 14.0% of its workEpidemiology: 1 fractional works · 8.4% of its workDermatology: 1 fractional works · 6.6% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 4.6% of its workEmergency Medicine: 0 fractional works · 1.7% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 1.1% of its workRehabilitation: 0 fractional works · 1.1% of its workNeurology: 0 fractional works · 1.0% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 0.6% of its workPulmonary and Respiratory Medicine: 0 fractional works · 0.6% of its workRheumatology: 0 fractional works · 0.6% of its workSocial Sciences: 1 fractional works · 6.0% of its workSocial Sciences: 1 fractional works · 6.0% of its workHealth: 1 fractional works · 6.0% of its workPhysical Sciences: 0 fractional works · 0.5% of its workEngineering: 0 fractional works · 0.5% of its workBiomedical Engineering: 0 fractional works · 0.5% of its workALL ITS WORKVaxxas(Australia)10fractional works, all years
Life Sciences53%Physical Sciences1%Health Sciences40%Social Sciences6%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 8 fields, with their numbers
    1. Immunology and Microbiology216.6%
    2. Pharmacology, Toxicology and Pharmaceutics215.2%
    3. Biochemistry, Genetics and Molecular Biology113.8%
    4. Agricultural and Biological Sciences16.7%
    5. Neuroscience00.7%
    1. Medicine440.3%
    1. Social Sciences16.0%
    1. Engineering00.5%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 2.15× its world share, 1 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 1.99× its world share, 1 worksBiochemistry, Geneti…Immunology and Microbiology: 15.05× its world share, 1 worksImmunology and Micro…Neuroscience: 0.72× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 32.53× its world share, 1 worksPharmacology, Toxico…Engineering: 0.06× its world share, 0 worksEngineeringMedicine: 2.08× its world share, 2 worksMedicineSocial Sciences: 0.83× its world share, 1 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 32.5×. Every wedge is a field page.

All 8 fields, with their numbers
  1. Pharmacology, Toxicology and Pharmaceutics32.53×1 works
  2. Immunology and Microbiology15.05×1 works
  3. Agricultural and Biological Sciences2.15×1 works
  4. Medicine2.08×2 works
  5. Biochemistry, Genetics and Molecular Biology1.99×1 works
  6. Social Sciences0.83×1 works
  7. Neuroscience0.72×0 works
  8. Engineering0.06×0 works

Who are the top researchers at Vaxxas (Australia)?

Ranked on the quality score, Angus Harry Forster and Ben Baker lead among researchers whose main affiliation is Vaxxas (Australia).

  1. 1 Angus Harry Forster Australia · #596,703 worldwide 1.9k citations · 39 works
  2. 2 Ben Baker Australia · #4,584,949 worldwide 179 citations · 22 works
All ranked researchers at Vaxxas (Australia)

What are the most cited papers from Vaxxas (Australia)?

The most cited paper from Vaxxas (Australia) is "Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™)" (Germain J. P. Fernando, Julian Hickling, Cesar M. Jayashi Flores et al., 2018), with 129 citations. Next come "Dissolvable polymer microneedles for drug delivery and diagnostics" (127) and "Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial" (102).

Most cited papers
#PaperReleasedCitations
1 Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™) Germain J. P. Fernando, Julian Hickling, Cesar M. Jayashi Flores et al. · Vaccine Open access 17 May 2018 129
2 Dissolvable polymer microneedles for drug delivery and diagnostics Masood Ali, Sarika Namjoshi, Heather A. E. Benson et al. · Journal of Controlled Release 24 May 2022 127
3 Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial Angus Harry Forster, Katey L. Witham, Alexandra C. I. Depelsenaire et al. · PLoS Medicine Open access 17 Mar 2020 102
4 Dry-Coated Live Viral Vector Vaccines Delivered by Nanopatch Microprojections Retain Long-Term Thermostability and Induce Transgene-Specific T Cell Responses in Mice Frances Elizabeth Pearson, Celia L. McNeilly, Michael Lawrence Crichton et al. · PLoS ONE Open access 9 Jul 2013 73
5 Transcription regulation of MYB: a potential and novel therapeutic target in cancer Partha Mitra · Annals of Translational Medicine Open access Nov 2018 72
All 37 most cited papers, with filters and sorting

Which research topics does Vaxxas (Australia) publish most on?

By volume in 2022-now: SARS-CoV-2 and COVID-19 Research, Vaccine Coverage and Hesitancy, Animal Virus Infections Studies and Immunotherapy and Immune Responses.

SARS-CoV-2 and COVID-19 Research: 1 fractional worksVaccine Coverage and Hesitancy: 1 fractional worksAnimal Virus Infections …1Animal Virus Infections Studies: 1 fractional worksImmunotherapy and Immune…1Immunotherapy and Immune Responses: 1 fractional worksAdvancements in Transder…1Advancements in Transdermal Drug Delivery: 1 fractional worksVirus-based gene therapy…0Virus-based gene therapy research: 0 fractional worksDermatology and Skin Diseases: 0 fractional worksVirology and Viral Diseases: 0 fractional worksContact Dermatitis and Allergies: 0 fractional worksT-cell and B-cell Immunology: 0 fractional works
Infectious DiseasesHealthAnimal Science and ZoologyImmunology4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 SARS-CoV-2 and COVID-19 Research Infectious Diseases 1 works
  2. 2 Vaccine Coverage and Hesitancy Health 1 works
  3. 3 Animal Virus Infections Studies Animal Science and Zoology 1 works
  4. 4 Immunotherapy and Immune Responses Immunology 1 works
  5. 5 Advancements in Transdermal Drug Delivery Pharmaceutical Science 1 works
  6. 6 Virus-based gene therapy research Genetics 0 works
  7. 7 Dermatology and Skin Diseases Dermatology 0 works
  8. 8 Virology and Viral Diseases Epidemiology 0 works
  9. 9 Contact Dermatitis and Allergies Dermatology 0 works
  10. 10 T-cell and B-cell Immunology Immunology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available95.4%not open4.6%

World: 40% of research is openly available.

with international co-authors31.5%domestic only68.5%

World: 18% is written across borders.

How has Vaxxas (Australia)'s research output changed?

Output in 2022-2025 was 67% higher than in 2018-2021.

still counting201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Vaxxas (Australia) as a percentage of every work published that year, 0.000022% in 2024.

still counting0.000020%0.000040%0.000060%Vaxxas (Australia)0.000020% in 20252020

Fractional works of Vaxxas (Australia) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Brisbane

All research institutions in Brisbane

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Vaxxas (Australia). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.